Double hit lymphoma: The MD Anderson Cancer Center clinical experience

British Journal of Haematology

Volumn 166, Issue 6, 2014, Pages 891-901

  Oki, Yasuhiro ^a   Noorani, Mansoor ^a   Lin, Pei ^a   Davis, Richard E ^a   Neelapu, Sattva S ^a   Ma, Long ^a   Ahmed, Mohamed ^a   Rodriguez, Maria Alma ^a   Hagemeister, Fredrick B ^a   Fowler, Nathan ^a   Wang, Michael ^a   Fanale, Michelle A ^a   Nastoupil, Loretta ^a   Samaniego, Felipe ^a   Lee, Hun J ^a   Dabaja, Bouthaina S ^a   Pinnix, Chelsea C ^a   Medeiros, Leonard J ^a   Nieto, Yago ^a   Khouri, Issa ^a   Kwak, Larry W ^a   Turturro, Francesco ^a   Romaguera, Jorge E ^a   Fayad, Luis E ^a   Westin, Jason R ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BCL2; BCL6; Double hit lymphoma; MYC; Prognostic factors

Indexed keywords

ANTHRACYCLINE; BENDAMUSTINE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CENTER; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOUBLE HIT LYMPHOMA; EVENT FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; VERY ELDERLY;

BCL2; BCL6; DOUBLE HIT LYMPHOMA; MYC; PROGNOSTIC FACTORS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; GENES, BCL-2; GENES, MYC; HUMANS; LYMPHOMA, B-CELL; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84907599085     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12982     Document Type: Article

References (26)

1. Aukema, S.M., Siebert, R., Schuuring, E., van Imhoff, G.W., Kluin-Nelemans, H.C., Boerma, E.J. & Kluin, P.M. (2011) Double-hit B-cell lymphomas. Blood, 117, 2319-2331.
2. Bertrand, P., Bastard, C., Maingonnat, C., Jardin, F., Maisonneuve, C., Courel, M.N., Ruminy, P., Picquenot, J.M. & Tilly, H. (2007) Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia, 21, 515-523.
3. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
4. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
5. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
6. Fine, J.P. (2001) Regression modeling of competing crude failure probabilities. Biostatistics, 2, 85-97.
7. Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., Glick, J.H., Coltman, C.A. Jr & Miller, T.P. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1002-1006.
8. Friedberg, J.W. (2012) Double-hit diffuse large B-cell lymphoma. Journal of Clinical Oncology, 30, 3439-3443.
9. Gooley, T.A., Leisenring, W., Crowley, J. & Storer, B.E. (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine, 18, 695-706.
10. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Muller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. & Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-282.
11. Johnson, N.A., Savage, K.J., Ludkovski, O., Ben-Neriah, S., Woods, R., Steidl, C., Dyer, M.J., Siebert, R., Kuruvilla, J., Klasa, R., Connors, J.M., Gascoyne, R.D. & Horsman, D.E. (2009) Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood, 114, 2273-2279.
12. Kanungo, A., Medeiros, L.J., Abruzzo, L.V. & Lin, P. (2006) Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Modern Pathology, 19, 25-33.
13. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of American Statistical Association, 53, 457-481.
14. Le Gouill, S., Talmant, P., Touzeau, C., Moreau, A., Garand, R., Juge-Morineau, N., Gaillard, F., Gastinne, T., Milpied, N., Moreau, P., Harousseau, J.L. & Avet-Loiseau, H. (2007) The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica, 92, 1335-1342.
15. Li, S., Lin, P., Fayad, L.E., Lennon, P.A., Miranda, R.N., Yin, C.C., Lin, E. & Medeiros, L.J. (2012) B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Modern Pathology, 25, 145-156.
16. Macpherson, N., Lesack, D., Klasa, R., Horsman, D., Connors, J.M., Barnett, M. & Gascoyne, R.D. (1999) Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. Journal of Clinical Oncology, 17, 1558-1567.
17. Niitsu, N., Okamoto, M., Miura, I. & Hirano, M. (2009) Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia, 23, 777-783.
18. Oki, Y., Westin, J.R., Vega, F., Chuang, H., Fowler, N., Neelapu, S., Hagemeister, F.B., McLaughlin, P., Kwak, L.W., Romaguera, J.E., Fanale, M., Younes, A., Rodriguez, M.A., Orlowski, R.Z., Wang, M., Ouzounian, S.T., Samaniego, F. & Fayad, L. (2013) Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. British Journal of Haematology, 163, 611-620.
19. Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., Bokemeyer, C., Eimermacher, H., Ho, A., Hoffmann, M., Mertelsmann, R., Trumper, L., Balleisen, L., Liersch, R., Metzner, B., Hartmann, F., Glass, B., Poeschel, V., Schmitz, N., Ruebe, C., Feller, A.C. & Loeffler, M. (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). The Lancet Oncology, 9, 105-116.
20. Snuderl, M., Kolman, O.K., Chen, Y.B., Hsu, J.J., Ackerman, A.M., Dal Cin, P., Ferry, J.A., Harris, N.L., Hasserjian, R.P., Zukerberg, L.R., Abramson, J.S., Hochberg, E.P., Lee, H., Lee, A.I., Toomey, C.E. & Sohani, A.R. (2010) B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. American Journal of Surgical Pathology, 34, 327-340.
21. Stiff, P.J., Unger, J.M., Cook, J.R., Constine, L.S., Couban, S., Stewart, D.A., Shea, T.C., Porcu, P., Winter, J.N., Kahl, B.S., Miller, T.P., Tubbs, R.R., Marcellus, D., Friedberg, J.W., Barton, K.P., Mills, G.M., LeBlanc, M., Rimsza, L.M., Forman, S.J. & Fisher, R.I. (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 369, 1681-1690.
22. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer, Lyon, France.
23. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New England Journal of Medicine, 329, 987-994.
24. Tomita, N., Tokunaka, M., Nakamura, N., Takeuchi, K., Koike, J., Motomura, S., Miyamoto, K., Kikuchi, A., Hyo, R., Yakushijin, Y., Masaki, Y., Fujii, S., Hayashi, T., Ishigatsubo, Y. & Miura, I. (2009) Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica, 94, 935-943.
25. Wilson, W.H., Grossbard, M.L., Pittaluga, S., Cole, D., Pearson, D., Drbohlav, N., Steinberg, S.M., Little, R.F., Janik, J., Gutierrez, M., Raffeld, M., Staudt, L., Cheson, B.D., Longo, D.L., Harris, N., Jaffe, E.S., Chabner, B.A., Wittes, R. & Balis, F. (2002) Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood, 99, 2685-2693.
26. Wilson, W.H., Dunleavy, K., Pittaluga, S., Hegde, U., Grant, N., Steinberg, S.M., Raffeld, M., Gutierrez, M., Chabner, B.A., Staudt, L., Jaffe, E.S. & Janik, J.E. (2008) Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. Journal of Clinical Oncology, 26, 2717-2724.